Merck KGaA Shares Jump on Expected Return to Sales Growth in 2024
By Adria Calatayud
Shares of Germany's Merck KGaA rose after the company forecast a return to organic sales growth next year, supported by recovering demand for semiconductor materials and abating Covid-19 headwinds.
At 0749 GMT on Thursday, Merck's shares traded 5.4% higher at EUR153.40.
The life-sciences and electronics group confirmed it expects a broadly stable top-line performance this year, with sales ranging from a 2% fall to a 2% rise and resulting in total net sales of 20.5 billion euros and 21.9 billion euros ($21.60 billion-$23.08 billion).
Analysts polled by FactSet expect Merck's sales to be EUR21.33 billion this year, growing to EUR22.46 billion in 2024.
Merck said weakening Covid-19 sales should be less of a headwind next year than in 2023 for its life-sciences segment, while the semiconductor-material market served by its electronics segment is expected to recover incrementally in 2024.
The company also reiterated medium-term targets for its division and said exposure to structural trends give it confidence in continuing to grow beyond 2025.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
October 19, 2023 04:07 ET (08:07 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom